A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg

NCT04332874 PHASE2 RECRUITING

The purpose of this study is to find out whether giving the study drug pembrolizumab in combination with the chemotherapy drugs melphalan and dactinomycin, delivered directly to the affected arm or leg using a technique called isolated limb infusion (ILI), is a safe treatment that can delay the time before your disease gets worse (progresses).

Details

Lead sponsor	Memorial Sloan Kettering Cancer Center
Phase	PHASE2
Status	RECRUITING
Enrolment	30
Start date	Wed Apr 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Apr 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Sarcoma
• Myxofibrosarcoma
• Undifferentiated Pleomorphic Sarcoma
• Alveolar Soft Part Sarcoma

Interventions

• Isolated Limb Infusion
• Pembrolizumab
• infusion of melphalan and dactinomycin

Countries

United States